Page last updated: 2024-10-31

nafamostat and Syndrome

nafamostat has been researched along with Syndrome in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Syndrome: A characteristic symptom complex.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ryu, HG1
Jung, CW1
Lee, CS1
Lee, J1

Trials

1 trial available for nafamostat and Syndrome

ArticleYear
Nafamostat mesilate attenuates Postreperfusion Syndrome during liver transplantation.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:5

    Topics: Adult; Benzamidines; Double-Blind Method; Female; Guanidines; Humans; Infusions, Intravenous; Kallik

2011